The National Institute for Health and Care Excellence (NICE) published advice in January 2015 in relation to eculizumab (Soliris®) for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS). At their meeting on 11th February 2015 AWMSG supported the adoption and implementation of this advice within NHS Wales (refer to the minutes of meetings). The Minister for Health and Social Services has subsequently agreed that the NICE HST advice for eculizumab (Soliris®) should be implemented within NHS Wales. A National Clinical Access Policy will be developed by Welsh Health Specialised Services Committee (WHSSC) with the support of clinical experts, patient representatives and other key stakeholders. Refer to the NICE website for full guidance including any specific restrictions on the use of the technology.